A vaccine given during pregnancy is significantly cutting hospital admissions among newborns with respiratory syncytial virus (RSV), with UK health officials confirming a decrease of more than 80 per cent. The jab, provided to pregnant women from 28 weeks of gestation since 2024, protects babies from birth by boosting maternal immunity and transferring immunity through the placenta. A major new study analysing nearly 300,000 births across England between September 2024 and March 2025 has shown the vaccine’s “excellent protection” during the period when infants are most vulnerable to the virus. RSV affects roughly half of all newborns and remains one of the primary reasons of hospital admission in babies under one year old, with more than 20,000 serious cases recorded annually across the UK.
How the immunisation protects at-risk babies
RSV, or respiratory syncytial virus, is a frequent respiratory infection that affects roughly half of all newborns in their first few months of life. The virus can range from causing mild, cold-like symptoms to triggering severe chest infections that cause babies to struggle to breathe and feed. In the most severe cases, the inflammation in the lungs becomes life-threatening, with small numbers of infants dying from the infection each year. Dr Conall Watson, national programme lead for RSV at the UK Health Security Agency, emphasises the distressing nature of severe RSV infections: “In babies with severe infections you can see their chest and lungs struggling, as they attempt to draw enough oxygen in. This is extremely frightening as a parent, frightening for good reason.”
The pregnancy vaccine functions by stimulating the mother’s immune system to produce defence proteins, which are then passed to the foetus through the placenta. This maternal immunity offers newborns with immediate protection from the point of delivery, precisely when they are highly susceptible to RSV. The new study shows that protection reaches approximately 85% when the vaccine is given at least four weeks before delivery. Even shorter intervals between vaccination and birth can still deliver meaningful protection, with evidence suggesting that a fortnight’s interval is adequate to shield babies delivered prematurely. Dr Watson advises pregnant women to have the vaccine on schedule, whilst observing that protection can still occur even if given later in the third trimester.
- Nearly 85 per cent coverage when immunised 4 weeks before birth
- Maternal antibodies transferred through placenta safeguard newborns from birth
- Protection achievable with 2-week gap before early delivery
- Vaccination during third trimester still offers meaningful infant protection
Compelling evidence from the latest research
The effectiveness of the pregnancy RSV vaccine has been established through a thorough investigation conducted across England, analysing data from approximately 300,000 babies born between September 2024 and March 2025. This represents approximately 90% of all births during that half-year window, providing strong and reliable information of the vaccine’s real-world impact. The study’s conclusions have been validated by the UK Health Security Agency as showing robust protection for newborns during their earliest and most vulnerable period. The breadth of this investigation gives healthcare professionals and expectant parents with confidence in the vaccine’s proven efficacy across varied populations and settings.
The results paint a compelling picture of the vaccine’s protective effectiveness. More than 4,500 babies were admitted to hospital with RSV during the study period, with the overwhelming majority being infants whose mothers had not been given the vaccination. This clear distinction emphasises the vaccine’s vital importance in preventing serious illness in newborns. The reduction in hospital admissions surpassing 80 per cent represents a major public health success, possibly preventing thousands of infants from experiencing the frightening and potentially life-threatening symptoms connected with severe RSV infection. These findings reinforce the importance of the vaccination programme introduced in the UK in 2024.
Methodology and scope of study
The research reviewed birth and hospitalisation records from England over a six-month period, capturing data on approximately 90% of all births during this timeframe. By examining around 300,000 babies born to vaccinated and unvaccinated mothers, researchers were in a position to determine direct comparisons of RSV infection levels and hospital admissions. The sizeable sample and thorough nature of the data collection ensured that findings were statistically significant and indicative of the general population, rather than isolated cases or small subgroups.
The study specifically recorded hospital admissions for RSV among infants born to mothers who had received the vaccine at varying intervals before delivery. This allowed researchers to determine the minimum time required between vaccination and birth for maximum protection, as well as to determine whether protection continued to be effective with briefer timeframes. The methodology measured practical outcomes rather than experimental conditions, providing tangible evidence of how the vaccine works when given across varied healthcare environments and patient circumstances throughout the third trimester of pregnancy.
| Key Finding | Impact |
|---|---|
| Nearly 85% protection with four-week vaccination interval | Optimal protection achieved when vaccine given one month before delivery |
| Over 80% reduction in newborn hospital admissions | Thousands of infants prevented from serious RSV-related illness annually |
| Vast majority of hospitalisations in unvaccinated mothers’ babies | Clear evidence of vaccine efficacy in preventing severe infection |
| Protection possible with two-week pre-birth interval | Meaningful safeguard even for early deliveries and shorter vaccination windows |
Grasping RSV and its threats
Respiratory syncytial virus, typically known as RSV, is among the primary causes of hospital admission in infants aged under twelve months across the United Kingdom. The virus affects roughly fifty per cent of all newborns during their first few months of life, with severity varying dramatically from mild cold-like symptoms to severe, life-threatening chest infections. More than 20,000 babies require intensive hospital care for RSV annually in the UK alone, placing enormous strain on paediatric wards and neonatal units during busier periods.
The infection causes inflammation deep within the lungs and airways, making it dangerously difficult for vulnerable newborns to feed and breathe adequately. Parents commonly see their babies struggling visibly, their chests heaving as they attempt to draw sufficient oxygen into their weakened respiratory system. Whilst most infants get better with clinical support, a small but significant group succumb from respiratory syncytial virus complications yearly, making vaccination as prevention a essential public health imperative for defending the most vulnerable and youngest members of society.
- RSV produces inflammation in lungs, leading to serious respiratory problems in babies
- Approximately half of infants catch the infection in their first few months of life
- Symptoms vary between mild colds to serious chest infections that threaten life needing hospital treatment
- Over 20,000 UK infants need serious hospital treatment for RSV annually
- A small number of infants succumb to RSV related complications each year in the UK
Take-up rates and specialist advice
Since the RSV vaccine programme commenced in 2024, health officials have highlighted the importance of pregnant women receiving their jab at the ideal time for greatest protection. Dr Conall Watson, lead for the national programme for RSV at the UK Health Security Agency, has underscored that timing is crucial for ensuring newborns receive the most robust immunity from birth. Whilst the study demonstrates that vaccination performed at least four weeks prior to delivery offers approximately 85% protection, experts encourage women to receive their vaccine as early as possible from 28 weeks of pregnancy onwards to increase the antibodies passed to their babies through the placenta.
The communication from public health bodies remains clear: pregnant women ought to prioritise vaccination during their final three months, even if circumstances mean they cannot receive the jab at the optimal time. Dr Watson has provided reassurance to expectant mothers that protection remains still achievable with reduced timeframes between immunisation and delivery, including even a fourteen-day window for those delivering slightly early. This adaptable strategy acknowledges the realities of pregnancy and childbirth whilst ensuring strong safeguarding for at-risk infants during their earliest and most vulnerable period when RSV represents the highest danger of serious illness.
Regional disparities in vaccination
Whilst the RSV vaccine programme has been rolled out across England, uptake rates and implementation timelines have differed across various areas and NHS trusts. Some areas have attained higher vaccination coverage among qualifying expectant mothers, whilst others continue working to increase awareness and access to the jab. These regional differences demonstrate differences across healthcare infrastructure, engagement approaches, and local engagement efforts, though the overall statistics demonstrates robust and reliable protection regardless of geographical location.
- NHS trusts rolling out multiple messaging strategies to engage with pregnant women
- Geographic variations in vaccination coverage levels across England require targeted improvement
- Regional health providers tailoring initiatives to meet local requirements and situations
Real-world impact and parent viewpoints
The vaccine’s outstanding effectiveness translates into real advantages for families throughout the United Kingdom. With over 20,000 babies admitted to hospital annually due to RSV before the introduction of this safeguarding intervention, the 80% drop in admissions equates to thousands of infants shielded from serious illness. Parents no more face the upsetting situation of watching their newborns gasping for air or struggle to eat, symptoms that characterise critical RSV illness. The vaccine has substantially transformed the picture of neonatal respiratory health, providing expectant mothers a preventative option to safeguard their youngest infants during those crucial first weeks.
For families like that of Malachi, whose acute RSV infection led to devastating brain damage, the vaccine’s availability carries profound emotional significance. His mother’s promotion of the jab emphasises the life-altering consequences that preventable illness can inflict on young children and their families. Whilst Malachi’s experience comes before the vaccine programme, his story strikes a chord with parents now offered protection. The knowledge that such significant complications—hospital stay, oxygen dependency, neurological damage—are now largely avoidable has given considerable reassurance to expectant mothers in their third trimester, changing what was once an predictable seasonal threat into a controllable health concern.